• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osimertinib for Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma.

作者信息

Okabe Naoyuki, Takagi Hironori, Mine Hayato, Fukai Satoshi, Minemura Hiroyuki, Suzuki Hiroyuki

机构信息

Respiratory Surgery, Takeda General Hospital, Aizuwakamatsu, Japan.

Initial Training Physicians, Takeda General Hospital, Aizuwakamatsu, Japan.

出版信息

J Thorac Oncol. 2017 Oct;12(10):e167-e169. doi: 10.1016/j.jtho.2017.06.071.

DOI:10.1016/j.jtho.2017.06.071
PMID:28939151
Abstract
摘要

相似文献

1
Osimertinib for Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma.奥希替尼用于转化为T790M阳性鳞状细胞癌的表皮生长因子受体突变阳性肺腺癌
J Thorac Oncol. 2017 Oct;12(10):e167-e169. doi: 10.1016/j.jtho.2017.06.071.
2
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M-Positive Non-Small Cell Lung Adenocarcinoma.EGFRmt T790M阳性非小细胞肺腺癌脉络膜转移对奥希替尼的反应
J Thorac Oncol. 2017 Oct;12(10):e165-e167. doi: 10.1016/j.jtho.2017.06.001.
3
Osimertinib for Secondary T790M-Mutation-Positive Squamous Cell Carcinoma Transformation After Afatinib Failure.奥希替尼用于阿法替尼治疗失败后的继发性T790M突变阳性鳞状细胞癌转化
J Thorac Oncol. 2018 Dec;13(12):e252-e254. doi: 10.1016/j.jtho.2018.07.100.
4
Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma.奥希替尼剂量递增可诱导进展性EGFR T790M突变型柔脑膜肺腺癌消退。
J Thorac Oncol. 2017 Nov;12(11):e188-e190. doi: 10.1016/j.jtho.2017.07.029.
5
First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.对携带活性表皮生长因子受体突变的肺鳞状细胞癌患者进行一线奥希替尼治疗。
Lung Cancer. 2020 Feb;140:113-115. doi: 10.1016/j.lungcan.2019.11.012. Epub 2019 Nov 18.
6
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.奥希替尼治疗表皮生长因子受体（EGFR）T790M突变阳性非小细胞肺癌的安全性和有效性。
Expert Rev Anticancer Ther. 2016;16(4):383-90. doi: 10.1586/14737140.2016.1162103. Epub 2016 Mar 21.
7
Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.奥希替尼治疗肺鳞癌 1 例并文献复习
Intern Med. 2021 Apr 1;60(7):1067-1071. doi: 10.2169/internalmedicine.5463-20. Epub 2020 Nov 2.
8
Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.再次活检后进行穿插治疗与奥希替尼治疗的无进展生存期缩短相关。
Cancer Res Treat. 2018 Oct;50(4):1164-1174. doi: 10.4143/crt.2017.460. Epub 2017 Dec 11.
9
Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.基于脑脊液中EGFR T790M耐药突变的检测，用奥希替尼治疗一名非小细胞肺癌患者。
Lung Cancer. 2017 Dec;114:111-112. doi: 10.1016/j.lungcan.2017.10.010. Epub 2017 Oct 28.
10
Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.表皮生长因子受体酪氨酸激酶抑制剂耐药后 T790M 阳性肺腺癌的临床特征，重点是脑转移和生存。
Lung Cancer. 2018 Jul;121:12-17. doi: 10.1016/j.lungcan.2018.04.013. Epub 2018 Apr 17.

引用本文的文献

1
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.奥希替尼治疗初治 EGFR T790M 阳性肺鳞癌的疗效：病例报告及文献复习。
Thorac Cancer. 2023 Oct;14(28):2886-2889. doi: 10.1111/1759-7714.15081. Epub 2023 Aug 28.
2
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.下一代测序技术阐明了为什么在 EGFR 突变型肺鳞癌的尸检病例中，一线奥希替尼治疗无效。
Thorac Cancer. 2023 Mar;14(7):709-713. doi: 10.1111/1759-7714.14807. Epub 2023 Jan 29.
3
Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review.
腺癌向鳞状细胞癌转化作为表皮生长因子受体酪氨酸激酶抑制剂耐药的一个来源：一例病例报告及文献综述
Front Oncol. 2022 Sep 8;12:942084. doi: 10.3389/fonc.2022.942084. eCollection 2022.
4
Long-Term Clinical Benefit in -Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report.表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKI）耐药后伴有局部鳞状细胞癌转化的 - 突变型肺腺癌的长期临床获益：一例报告
Front Oncol. 2022 May 26;12:883367. doi: 10.3389/fonc.2022.883367. eCollection 2022.
5
Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.表皮生长因子受体-酪氨酸激酶抑制剂初治的非小细胞肺癌中的基因改变
Oncol Lett. 2020 Jun;19(6):4169-4176. doi: 10.3892/ol.2020.11524. Epub 2020 Apr 8.
6
Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.奥希替尼治疗携带T790M突变且发生鳞状细胞转化的肺腺癌的疗效：一例报告及文献综述
Mol Clin Oncol. 2019 Aug;11(2):127-131. doi: 10.3892/mco.2019.1880. Epub 2019 Jun 13.